HUTCHMED DRC (HCM)
HUTCHMED DRC (HCM) is a NASDAQ-listed depositary receipt representing common stock of HUTCHMED (China) Limited, a Hong Kong-based biopharmaceutical company. Through its subsidiaries, the group discovers, develops, and commercializes targeted therapies and immunotherapies for cancer and immune-related diseases in Hong Kong, the United States, and other international markets. Its portfolio includes marketed and pipeline assets such as Fruquintinib, Savolitinib, Surufatinib, Sovleplenib, Tazemetostat, Fanregratinib, and Ranosidenib, along with earlier-stage candidates including HMPL-760 and HMPL-506. The company also maintains collaboration agreements with partners including AstraZeneca, Lilly, Takeda, Inmagene Biopharmaceuticals, Innovent Biologics, and Epizyme. Formerly known as Hutchison China MediTech Limited, the company adopted its current name in May 2021.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HCM
|
$14.12
|
25.6% Upside
|
Undervalued
|
$22.62
|
101.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
4.5x
|
1.7x
|
3.7x
|
2.001 B
|
791.3 M
|
4.6%
|
59.7%
|
9.7
|
—
|
-17.2%
|
